Transgenically-expressed secretoglobin 3A2 accelerates resolution of XXXX -induced @entity3794 in @entity19 .

@entity1 @entity82 @entity19 @entity59897 @entity3794 @entity720 @entity1732
BACKGROUND: Secretoglobin ( @entity59897 , a cytokine-like secretory protein of small molecular weight, is predominantly expressed in airway epithelial cells. While @entity59897 is known to have anti-inflammatory, growth factor, and anti-fibrotic activities, whether @entity59897 has any other roles, particularly in lung homeostasis and disease has not been demonstrated in vivo. The aim of this study was to address these questions in @entity19 . METHODS: A transgenic @entity19 line that expresses @entity59897 in the lung using the @entity1 surfactant protein-C promoter was established. Detailed histological, immunohistochemical, physiological, and molecular characterization of the @entity59897 -transgenic @entity19 lungs were carried out. @entity59897 -transgenic and wild-type @entity19 were subjected to @entity1732 -induced @entity3794 model, and their lungs and bronchoalveolar lavage fluids were collected at various time points during 9  weeks post- @entity1732 treatment for further analysis. RESULTS: Adult @entity59897 -transgenic @entity19 lungs expressed approximately five-fold higher levels of @entity59897 protein in comparison to wild-type @entity19 as determined by western blotting of lung tissues. Immunohistochemistry showed that expression was localized to alveolar type II cells in addition to airway epithelial cells, thus accurately reflecting the site of surfactant protein-C expression. @entity59897 - @entity19 showed normal lung development and histology, and no overt gross phenotypes. However, when subjected to a @entity1732 -induced @entity3794 model, they initially exhibited exacerbated @entity82 at 3  weeks post- @entity1732 administration that was more rapidly resolved by 6  weeks as compared with wild-type @entity19 , as determined by lung histology, Masson Trichrome staining and @entity720 content, inflammatory cell numbers, expression of collagen genes, and proinflammatory cytokine levels. The decrease of @entity82 coincided with the increased expression of @entity59897 in @entity59897 -transgenic lungs. CONCLUSIONS: These results demonstrate that @entity59897 is an anti-fibrotic agent, and suggest a possible therapeutic use of recombinant @entity59897 in the treatment of @entity3794 .
